Skip to main content
. 2022 Nov 16;9:1051157. doi: 10.3389/fnut.2022.1051157

FIGURE 5.

FIGURE 5

L-Ornithine L-Aspartate (LOLA) does not reverse myosteatosis in late-stage NASH. (A) LOLA was administered in drinking water to HFD-fed FOZ mice (HFD + LOLA) for the last 8 weeks of the 20-weeks dietary experiment. Treated mice were compared with FOZ HFD given plain water (HFD). (B) Plasma ammonia concentrations measured in systemic blood from HFD and HFD + LOLA after 20 weeks of diet (n = 5–10); (C) Dorsal muscle-to-spleen density measured in vivo by micro-CT in HFD and HFD + LOLA (n = 5–10); (D) Dorsal muscle area (L4–L5 averaged) measured in vivo by micro-CT in HFD and HFD + LOLA (n = 5–10); (E) 4-limb grip strength measured in HFD and HFD + LOLA (n = 5–10); (F) Wheat-germ agglutinin (WGA) staining of myofibers performed on paraffin-embedded quadriceps sections; (G) Quantification of myofibers size performed on quadriceps WGA-stained sections (n = 5–10). All data are represented as mean ± SD, *p < 0.05. Statistical tests used: (G) Unpaired two-tailed t-test. (B–E) Repeated-measures two-way ANOVA followed by post hoc Bonferroni correction.